Enterprise Value to EBITDA Ratio: Erasca, Inc. (ERAS)
Erasca, Inc. (ERAS) minimizes biological threats by developing treatments against RAS mutations for various types of neoplasms. Its therapeutic environment ensures full loyalty from trial participants, while R&D development is fueled by licensing deals. Competent management sets the strategic vector, providing transparent disclosure of research progress. This chart of current market quotes demonstrates an EV/EBITDA multiple of 0.00.
ERAS (erasca.com): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
ERAS - Net Income|Projected Future Earnings Erasca, Inc.|ERAS - P/E Multiple|Projected Price to Earnings Erasca, Inc.|ERAS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Erasca Oncology|ERAS - Operating income before deduction of amortization|Earnings per share for the last twelve months Erasca|ERAS - Earnings per share for the last 12 months|Quarterly EPS earnings growth erasca.com|ERAS - Net earnings per share growth this year|Expected earnings per share growth for next year Erasca, Inc.
Summary company analysis:Erasca Corp ERAS
When assessing the resilience of Erasca, Inc. (ERAS) to external shocks, it is essential to consider that the development of oncology drugs remains independent of macroeconomic cycles and GDP. Operational success here is dictated exclusively by the progress of clinical trials. The historical EV/EBITDA values for Erasca, Inc. (ERAS) reflect the ratio of the total enterprise value to earnings before interest, taxes, depreciation, and amortization. This indicator allows for an objective measurement of the fundamental value of assets by excluding the impact of debt load.
Competitors of Erasca, Inc.
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|EV/EBITDA Multiple DCTH|YMAB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aura Biosciences AURA|Business Value to Operating Income Before Depreciation CADL|Accuray Inc. - EV/EBITDA Multiple|SLS - EV/EBITDA Multiple|Actuate Therapeutics, Inc. (ACTU) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|HURA (TuHURA Biosciences Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Protara Therapeutics Inc (TARA)|EV/EBITDA Multiple FATE|EV/EBITDA Multiple aadibio.com (WHWK)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CSBR|XBiotech USA - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio CEL-SCI Corporation CVM|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RADX|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Adlai Nortye Limited (ANL)|Enterprise Value to EBITDA Ratio VERU (Veru)|Total Company Value to Operating Income Before Depreciation Ratio Tempest Therapeutics Inc|EV/EBITDA Multiple XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Company Value to EBITDA|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation KAPA (Kairos Pharma Ltd)|OKUR: EV/EBITDA Multiple|CytoMed Therapeutics Limited (GDTC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis Inc.|Apollomics Corp (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THAR|Enterprise Value to EBITDA Ratio advanbiomed.com ADVB|EV/EBITDA Multiple GNPX (Genprex)|EV/EBITDA Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XBIO (Xenetic Biosciences) - Enterprise Value to Operating Income Before Depreciation|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Company Value to EBITDA BeiGene Ltd. BGNE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|ELEV (Elevation Oncology Inc.) - Business Value to Operating Income Before Depreciation|iCAD - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IKNA|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
